<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK174884" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK174884/" /><meta name="ncbi_pagename" content="Familial Hypercholesterolemia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Familial Hypercholesterolemia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Familial Hypercholesterolemia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/12/08" /><meta name="citation_author" content="Emily Youngblom" /><meta name="citation_author" content="Mitchel Pariani" /><meta name="citation_author" content="Joshua W Knowles" /><meta name="citation_pmid" content="24404629" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK174884/" /><meta name="citation_keywords" content="Familial Hypercholesterolæmia" /><meta name="citation_keywords" content="Hypercholesterolemia, Autosomal Dominant" /><meta name="citation_keywords" content="Hyperlipoproteinemia Type IIA" /><meta name="citation_keywords" content="Hypercholesterolemia, Autosomal Dominant" /><meta name="citation_keywords" content="Hyperlipoproteinemia, Type IIA" /><meta name="citation_keywords" content="Familial Hypercholesterolæmia" /><meta name="citation_keywords" content="Heterozygous FH (HeFH)" /><meta name="citation_keywords" content="Apolipoprotein B-100" /><meta name="citation_keywords" content="Low-density lipoprotein receptor" /><meta name="citation_keywords" content="Proprotein convertase subtilisin/kexin type 9" /><meta name="citation_keywords" content="APOB" /><meta name="citation_keywords" content="LDLR" /><meta name="citation_keywords" content="PCSK9" /><meta name="citation_keywords" content="Familial Hypercholesterolemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Familial Hypercholesterolemia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Emily Youngblom" /><meta name="DC.Contributor" content="Mitchel Pariani" /><meta name="DC.Contributor" content="Joshua W Knowles" /><meta name="DC.Date" content="2016/12/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK174884/" /><meta name="description" content="Familial hypercholesterolemia (FH) is characterized by severely elevated LDL cholesterol (LDL-C) levels that lead to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading to an increased risk for cardiovascular disease. Xanthomas (patches of yellowish cholesterol buildup) may worsen with age as a result of extremely high cholesterol levels. Xanthomas can occur around the eyelids and within the tendons of the elbows, hands, knees, and feet. In FH, the more common cardiovascular disease is coronary artery disease (CAD), which may manifest as angina and myocardial infarction; stroke occurs more rarely. Untreated men are at a 50% risk for a fatal or nonfatal coronary event by age 50 years; untreated women are at a 30% risk by age 60 years." /><meta name="og:title" content="Familial Hypercholesterolemia" /><meta name="og:type" content="book" /><meta name="og:description" content="Familial hypercholesterolemia (FH) is characterized by severely elevated LDL cholesterol (LDL-C) levels that lead to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading to an increased risk for cardiovascular disease. Xanthomas (patches of yellowish cholesterol buildup) may worsen with age as a result of extremely high cholesterol levels. Xanthomas can occur around the eyelids and within the tendons of the elbows, hands, knees, and feet. In FH, the more common cardiovascular disease is coronary artery disease (CAD), which may manifest as angina and myocardial infarction; stroke occurs more rarely. Untreated men are at a 50% risk for a fatal or nonfatal coronary event by age 50 years; untreated women are at a 30% risk by age 60 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK174884/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hyperchol/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK174884/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A37F7E04089E100000000076902A6.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK174884_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK174884_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/fhm/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hi/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK174884_"><span class="title" itemprop="name">Familial Hypercholesterolemia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Hypercholesterol&#x000e6;mia; Hypercholesterolemia, Autosomal Dominant; Hyperlipoproteinemia Type IIA</div><p class="contrib-group"><span itemprop="author">Emily Youngblom</span>, PhD, MPH, <span itemprop="author">Mitchel Pariani</span>, MS, LCGC, and <span itemprop="author">Joshua W Knowles</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK174884_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK174884_ai__"><div class="contrib half_rhythm"><span itemprop="author">Emily Youngblom</span>, PhD, MPH<div class="affiliation small">Stanford Center for Inherited Cardiovascular Disease<br />Stanford, California</div><div class="affiliation small">University of Washington School of Public Health<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@bgnuoye" class="oemail">ude.wu@bgnuoye</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mitchel Pariani</span>, MS, LCGC<div class="affiliation small">Stanford Center for Inherited Cardiovascular Disease<br />Stanford, California</div></div><div class="contrib half_rhythm"><span itemprop="author">Joshua W Knowles</span>, MD, PhD<div class="affiliation small">Stanford Center for Inherited Cardiovascular Disease<br />Stanford, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.drofnats@jelwonk" class="oemail">ude.drofnats@jelwonk</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 2, 2014</span>; Last Update: <span itemprop="dateModified">December 8, 2016</span>.</p><p><em>Estimated reading time: 35 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hyperchol.Summary" itemprop="description"><h2 id="_hyperchol_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Familial hypercholesterolemia (FH) is characterized by severely elevated LDL cholesterol (LDL-C) levels that lead to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading to an increased risk for cardiovascular disease. Xanthomas (patches of yellowish cholesterol buildup) may worsen with age as a result of extremely high cholesterol levels. Xanthomas can occur around the eyelids and within the tendons of the elbows, hands, knees, and feet. In FH, the more common cardiovascular disease is coronary artery disease (CAD), which may manifest as angina and myocardial infarction; stroke occurs more rarely. Untreated men are at a 50% risk for a fatal or nonfatal coronary event by age 50 years; untreated women are at a 30% risk by age 60 years.</p><p>An estimated 70%-95% of FH results from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of three genes (<i>APOB</i>, <i>LDLR</i>, <i>PCSK9</i>). FH is the most common inherited cardiovascular disease, with a prevalence of 1:200-250. FH likely accounts for 2%-3% of myocardial infarctions in individuals younger than age 60 years.</p><p>In contrast, <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> FH (HoFH) results from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (homozygous or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in one of these known genes (<i>APOB</i>, <i>LDLR</i>, <i>PCSK9</i>). Most individuals with HoFH experience severe CAD by their mid-20s and the rate of either death or coronary bypass surgery by the teenage years is high. Severe aortic stenosis is also common.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Several formal diagnostic criteria exist for FH. The diagnostic criteria most widely used in Western countries include: extreme hypercholesterolemia (untreated adults with LDL-C&#x0003e;190 mg/dL or total cholesterol levels &#x0003e;310 mg/dL; untreated children/adolescents with LDL-C levels &#x0003e;160 mg/dL or total cholesterol levels &#x0003e;230 mg/dL); history of premature CAD or other CVD; xanthomas; corneal arcus; and a family history of features suggestive of FH. The diagnosis of FH can also be established by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the three genes (<i>APOB</i>, <i>LDLR</i>, and <i>PCSK9</i>) known to be associated with FH.</p><p>The diagnosis of HoFH can be established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the three genes (<i>APOB</i>, <i>LDLR</i>, and <i>PCSK9</i>) known to be associated with FH.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Adults with FH: reduce CAD risk factors including cessation of smoking, regular physical activity, healthy diet, and weight control; treatment of hypertension; low-dose aspirin in high-risk individuals; pharmacotherapy (statins with additional medications as needed) to reduce lipid levels; referral to a lipid specialist if necessary to reduce LDL-C levels. Children with FH: referral to a lipid specialist; diet and lifestyle modifications; statins can be used in children starting around age eight years. Children and adults with HoFH: referral to a lipid specialist or specialized center for management of multiple drug therapy; LDL apheresis is often required; liver transplantation in rare circumstances.</p><p><i>Prevention of primary manifestations:</i> Statin-based therapy with addition of other medications as needed, in combination with a heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day); increased physical activity; not smoking.</p><p><i>Surveillance:</i> Children with an established diagnosis of FH or risk factors for FH (e.g., elevated serum cholesterol, a family history of FH, a family history of premature CAD or other CVD) should have lipid levels checked before age ten years. All individuals with FH should have lipid levels monitored as recommended. Individuals with HoFH should be monitored with various imaging modalities (including echocardiograms, CT angiograms, and cardiac catheterization) as recommended.</p><p><i>Agents/circumstances to avoid:</i> Smoking, high intake of saturated and trans unsaturated fat, excessive intake of cholesterol, sedentary lifestyle, obesity, hypertension, and diabetes mellitus.</p><p><i>Evaluation of relatives at risk:</i> Early diagnosis and treatment of first-degree and second-degree relatives at risk for FH can reduce morbidity and mortality. The genetic status of at-risk family members can be clarified by either: (1) <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member; or (2) measurement of LDL-C concentration.</p><p><i>Pregnancy management:</i> Pregnant women should incorporate all the recommended lifestyle changes including low saturated fat intake, no smoking, and high dietary soluble fiber. Statins are contraindicated in pregnancy due to concerns for teratogenicity and should be discontinued prior to conception. Bile acid binding resins (e.g., colesevelam) are generally considered safe (Class B for pregnancy), and LDL apheresis is also occasionally used if there is evidence of established CAD.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia (FH) and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> familial hypercholesterolemia (HoFH) are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p>Almost all individuals diagnosed with FH have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; the proportion of FH caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown but appears to be extremely low. Each child of an individual with FH has a 50% chance of inheriting the pathogenic variant.</p><p>If both parents have FH, each child has a 50% chance of having FH, a 25% chance of having HoFH, and a 25% chance of not having FH.</p><p>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in a family member with FH (or if both pathogenic variants have been identified in a family member with HoFH), prenatal testing for pregnancies at increased risk is possible.</p></div></div><div id="hyperchol.GeneReview_Scope"><h2 id="_hyperchol_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="hyperchol.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.Td_lrgtbl__"><table><thead><tr><th id="hd_h_hyperchol.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial Hypercholesterolemia: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Familial hypercholesterolemia (FH, also referred to as <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> FH or HeFH)</div></li><li class="half_rhythm"><div>Homozygous hypercholesterolemia (HoFH)</div></li></ul>
</td></tr></tbody></table></div></div></div><div id="hyperchol.Diagnosis"><h2 id="_hyperchol_Diagnosis_">Diagnosis</h2><p>In this <i>GeneReview</i>:</p><ul><li class="half_rhythm"><div>Familial hypercholesterolemia (FH) refers to hypercholesterolemia resulting from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of several genes (<i>APOB</i>, <i>LDLR</i>, and <i>PCSK9</i>); it is also referred to as heterozygous FH (HeFH). FH is a relatively common disorder (prevalence 1:200-1:250).</div></li><li class="half_rhythm"><div>Homozygous FH (HoFH) refers to <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (including true <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in one of these same genes (<i>APOB</i>, <i>LDLR</i>, and <i>PCSK9</i>). HoFH is much rarer than FH (prevalence 1:160,000 to 1:250,000 [<a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>, <a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</a>].</div></li></ul><div id="hyperchol.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Familial hypercholesterolemia (FH) <b>should be suspected</b> in individuals with the following findings:</p><ul><li class="half_rhythm"><div>Extreme hypercholesterolemia</div><ul><li class="half_rhythm"><div>Adults (untreated):</div><ul><li class="half_rhythm"><div>Low-density lipoprotein cholesterol (LDL-C) levels &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L)</div></li><li class="half_rhythm"><div>Total cholesterol levels &#x0003e;310 mg/dL (&#x0003e;8 mmol/L)</div></li></ul></li><li class="half_rhythm"><div>Children/adolescents (untreated):</div><ul><li class="half_rhythm"><div>LDL-C levels &#x0003e;130 mg/dL (&#x0003e;3.4 mmol/L)</div></li><li class="half_rhythm"><div>Total cholesterol levels &#x0003e;230 mg/dL (&#x0003e;6 mmol/L)</div></li></ul></li></ul></li><li class="half_rhythm"><div>History of premature coronary artery disease (CAD) or other cardiovascular disease (CVD) (e.g., angina pectoris, myocardial infarction, peripheral vascular disease)</div></li><li class="half_rhythm"><div>Physical examination findings (e.g., xanthomas, corneal arcus)</div></li><li class="half_rhythm"><div>Family history of premature CAD and/or CVD</div></li></ul></div><div id="hyperchol.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Currently three formal diagnostic criteria for FH are widely used in Western countries. (See <a class="bk_pop" href="#hyperchol.REF.haradashiba.2012.1043">Harada-Shiba et al [2012]</a> for criteria used in non-Western countries.)</p><ul><li class="half_rhythm"><div><a href="http://nlaresourcecenter.lipidjournal.com/Content/PDFs/Tables/5.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">US MEDPED Program</a></div></li><li class="half_rhythm"><div><a href="https://www.ncbi.nlm.nih.gov/books/NBK53810/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UK Simon Broome Familial Hypercholesterol&#x000e6;mia Registry</a></div></li><li class="half_rhythm"><div><a href="http://nlaresourcecenter.lipidjournal.com/Content/PDFs/Tables/4.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dutch Lipid Clinic Network</a></div></li></ul><p>All three criteria rely on a combination of the following:</p><ul><li class="half_rhythm"><div>Extreme hypercholesterolemia</div></li><li class="half_rhythm"><div>History of premature CAD or other CVD</div></li><li class="half_rhythm"><div>Findings on physical examination</div></li><li class="half_rhythm"><div>Family history of premature CAD or other CVD</div></li><li class="half_rhythm"><div>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with FH (see <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="fighypercholTmoleculargenetictestingus" rid-ob="figobhypercholTmoleculargenetictestingus">Table 1</a>)</div></li></ul><p><b>Extreme hypercholesterolemia</b></p><ul><li class="half_rhythm"><div>Adults (untreated):</div><ul><li class="half_rhythm"><div>LDL-C levels &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L)</div></li><li class="half_rhythm"><div>Total cholesterol levels &#x0003e;310 mg/dL (&#x0003e;8 mmol/L)</div></li></ul></li><li class="half_rhythm"><div>Children or adolescents (untreated):</div><ul><li class="half_rhythm"><div>LDL-C levels &#x0003e;160 mg/dL (&#x0003e;4 mmol/L)</div></li><li class="half_rhythm"><div>Total cholesterol levels &#x0003e;230 mg/dL (&#x0003e;6 mmol/L)</div></li></ul></li></ul><p>Note: (1) A non-fasting lipid panel can be obtained first in the initial evaluation of children, and, if abnormal or borderline, a fasting LDL-C level should be obtained [<a class="bk_pop" href="#hyperchol.REF.martin.2013">Martin et al 2013</a>]. Elevation of two consecutive LDL-C levels is often recommended to confirm the diagnosis. (2) Age-specific LDL-C or total cholesterol levels are more specific in determining the likelihood of FH; for instance, LDL-C or total cholesterol levels &#x0003e;95th percentile for age, gender, and country [<a class="bk_pop" href="#hyperchol.REF.starr.2008.791">Starr et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>]. (3) Computer (including mobile or smart phone-based) applications (see <a href="http://www.appdropp.com/ios/fh-diagnosis/543676258" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FH Diagnosis</a>) can assist with the determination of the likelihood of FH based on the formal diagnostic criteria.</p><p><b>History of premature CAD or other CVD</b></p><ul><li class="half_rhythm"><div>Angina pectoris</div></li><li class="half_rhythm"><div>Myocardial infarction</div></li><li class="half_rhythm"><div>Peripheral vascular diseases</div></li></ul><p>Note: Although stroke is possible, it is less common in FH than premature CAD [<a class="bk_pop" href="#hyperchol.REF.huxley.2003.22">Huxley et al 2003</a>].</p><p><b>Physical examination findings</b></p><ul><li class="half_rhythm"><div>Xanthomas (patches of yellowish cholesterol buildup). Common locations include around the eyelids, tendons of the elbows, hands, knees, and feet, particularly the Achilles tendon. Interdigital xanthomas occur in individuals with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> FH.</div></li><li class="half_rhythm"><div>Corneal arcus (white, gray, or blue opaque ring in the corneal margin). Because this becomes increasingly common in the general population with age, it is only diagnostic in younger individuals, particularly before age 45 years.</div></li></ul><p>Note: As statin treatment has become more common, it is possible that individuals have fewer visible signs of FH, complicating the application of the diagnostic criteria.</p><p><b>Family history of any of the following</b></p><ul><li class="half_rhythm"><div>Familial hypercholesterolemia</div></li><li class="half_rhythm"><div>High levels of LDL-C</div></li><li class="half_rhythm"><div>Early-onset (i.e., age &#x0003c;50 years) CAD (especially myocardial infarction)</div></li><li class="half_rhythm"><div>Xanthomas</div></li></ul><p><b>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with FH</b> (see <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="fighypercholTmoleculargenetictestingus" rid-ob="figobhypercholTmoleculargenetictestingus">Table 1</a>) is the gold standard for diagnosis accepted in many countries [<a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>].</p><ul><li class="half_rhythm"><div>The likelihood of identifying a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by molecular testing increases with higher LDL-C levels.</div></li><li class="half_rhythm"><div>In the United States, genetic testing is recommended when other laboratory tests have not definitively established the diagnosis of FH.</div></li></ul><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> can be considered. Sequence analysis of <i>LDLR</i> is performed first and followed by <i>LDLR</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found. Sequence analysis of <i>APOB</i> and <i>PCSK9</i> can be performed next if no pathogenic variant is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>APOB</i>, <i>LDLR</i>, <i>PCSK9</i>, and other genes of interest (see <a href="#hyperchol.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="hyperchol.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Familial Hypercholesterolemia (FH)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of FH Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>2</sup></th><th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by Method</th></tr><tr><th headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APOB</i></td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-5%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LDLR</i></td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-80%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%&#x000a0;<sup>7</sup></td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2.5%-10%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PCSK9</i></td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-3%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>10,&#x000a0;11</sup></td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-40%</td><td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hyperchol.TF.1.1"><p class="no_margin">See <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hyperchol.TF.1.2"><p class="no_margin">The yield for genetic testing varies by the pre-test probability of the disease as determined by the clinical diagnostic criteria. In "definite" FH the yield of genetic testing for identification of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> approaches 95%; in "probable" or "possible" FH the yield is lower (~70%) [<a class="bk_pop" href="#hyperchol.REF.motazacker.2012.1360">Motazacker et al 2012</a>, <a class="bk_pop" href="#hyperchol.REF.awan.2013.218">Awan et al 2013</a>].</p></div></dd><dt>3. </dt><dd><div id="hyperchol.TF.1.3"><p class="no_margin">See <a href="#hyperchol.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="hyperchol.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="hyperchol.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="hyperchol.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.huang.1989.11394">Huang et al [1989]</a></p></div></dd><dt>7. </dt><dd><div id="hyperchol.TF.1.7"><p class="no_margin">The majority of pathogenic variants in <i>LDLR</i> are detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, including those in the regulatory region (the majority occurring within 200 bp upstream of the initiation codon) if that region is targeted for sequencing [<a class="bk_pop" href="#hyperchol.REF.dedoussis.2004.443">Dedoussis et al 2004</a>].</p></div></dd><dt>8. </dt><dd><div id="hyperchol.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.horsthemke.1987.144">Horsthemke et al [1987]</a>, <a class="bk_pop" href="#hyperchol.REF.dedoussis.2004.443">Dedoussis et al [2004]</a>, <a class="bk_pop" href="#hyperchol.REF.bertolini.2013.342">Bertolini et al [2013]</a></p></div></dd><dt>9. </dt><dd><div id="hyperchol.TF.1.9"><p class="no_margin">No deletions or duplications involving <i>PCSK9</i> have been reported to cause <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia [<a class="bk_pop" href="#hyperchol.REF.de_castroor_s.2010.53">De Castro-Or&#x000f3;s et al 2010</a>].</p></div></dd><dt>10. </dt><dd><div id="hyperchol.TF.1.10"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.de_castroor_s.2010.53">De Castro-Or&#x000f3;s et al [2010]</a></p></div></dd><dt>11. </dt><dd><div id="hyperchol.TF.1.11"><p class="no_margin">It has been suggested that a <a class="def" href="/books/n/gene/glossary/def-item/polygenic/">polygenic</a> etiology is most likely in the majority of individuals with a clinical diagnosis of FH in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the three known genes can be identified. This suggestion is based on the presence in these individuals of a greater than average number of common LDL-C-raising variants (i.e., a high "LDL-SNP score") [<a class="bk_pop" href="#hyperchol.REF.talmud.2013.1293">Talmud et al 2013</a>].</p></div></dd></dl></div></div></div></div></div><div id="hyperchol.Clinical_Characteristics"><h2 id="_hyperchol_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hyperchol.Clinical_Description"><h3>Clinical Description</h3><div id="hyperchol.Familial_Hypercholesterolemia"><h4>Familial Hypercholesterolemia (FH)</h4><p><b>Coronary artery disease (CAD) and cardiovascular disease (CVD).</b> Elevated LDL cholesterol (LDL-C) leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading over time to an increased risk for cardiovascular disease (CVD), which by definition includes coronary artery disease (CAD) (manifest as angina and myocardial infarction) and stroke [<a class="bk_pop" href="#hyperchol.REF.scientific_steering_committee.1991.893">Scientific Steering Committee 1991</a>, <a class="bk_pop" href="#hyperchol.REF.versmissen.2008.a2423">Versmissen et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.elis.2011.223">Elis et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>]. In FH, CAD is the more common cardiovascular disease; stroke occurs more rarely and some evidence suggests that the risk for stroke may not be greater than in the general population [<a class="bk_pop" href="#hyperchol.REF.huxley.2003.22">Huxley et al 2003</a>].</p><p>All individuals with FH should be considered "high risk" (i.e., increased ~20-fold) for CAD. Recent data suggest that individuals with an LDL-C &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L) and a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="fighypercholTmoleculargenetictestingus" rid-ob="figobhypercholTmoleculargenetictestingus">Table 1</a> have a 22-fold increased risk for CAD while those without a pathogenic variant have a sixfold increased risk for CAD over the general population [<a class="bk_pop" href="#hyperchol.REF.khera.2016.2578">Khera et al 2016</a>].</p><p>Natural history studies from the pre-statin era suggest that untreated men are at 50% risk for a fatal or nonfatal coronary event by age 50 years; untreated women are at 30% risk by age 60 years [<a class="bk_pop" href="#hyperchol.REF.slack.1969.1380">Slack 1969</a>, <a class="bk_pop" href="#hyperchol.REF.stone.1974.476">Stone et al 1974</a>, <a class="bk_pop" href="#hyperchol.REF.civeira.2004.55">Civeira 2004</a>, <a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.reiner.2011.1769">Reiner et al 2011</a>]. See <a class="figpopup" href="/books/NBK174884/figure/hyperchol.F1/?report=objectonly" target="object" rid-figpopup="fighypercholF1" rid-ob="figobhypercholF1">Figure 1</a>. Of note, standard Framingham or other risk classification schemes are not applicable to persons with FH [<a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.reiner.2011.1769">Reiner et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighypercholF1" co-legend-rid="figlgndhypercholF1"><a href="/books/NBK174884/figure/hyperchol.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighypercholF1" rid-ob="figobhypercholF1"><img class="small-thumb" src="/books/NBK174884/bin/hyperchol-Image001.gif" src-large="/books/NBK174884/bin/hyperchol-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndhypercholF1"><h4 id="hyperchol.F1"><a href="/books/NBK174884/figure/hyperchol.F1/?report=objectonly" target="object" rid-ob="figobhypercholF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">LDL cholesterol burden in individuals with or without familial hypercholesterolemia as a function of the age of initiation of statin therapy Data derived from Starr et al [2008] and Huijgen et al [2012]. Figure from Nordestgaard et al [2013]; used by <a href="/books/NBK174884/figure/hyperchol.F1/?report=objectonly" target="object" rid-ob="figobhypercholF1">(more...)</a></p></div></div><p>Lipid-lowering therapy with statin-based regimens (see <b>Management</b>, <a href="#hyperchol.Treatment_of_Manifestations">Treatment of Manifestations</a>) significantly increases survival [<a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>, <a class="bk_pop" href="#hyperchol.REF.vuorio.2013.315">Vuorio et al 2013</a>] and reduces morbidity [<a class="bk_pop" href="#hyperchol.REF.versmissen.2008.a2423">Versmissen et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.elis.2011.223">Elis et al 2011</a>]. Additional medications such as ezetimibe, bile acid binding resins, or PCSK9 inhibiters are often necessary to achieve optimal LDL-C reduction [<a class="bk_pop" href="#hyperchol.REF.gidding.2015.2167">Gidding et al 2015</a>].</p><p>Data from the CASCADE-FH registry reveals that upwards of 61% of adults with FH have at least one modifiable cardiovascular risk factor. Coronary heart disease was reported in 47% of men with FH, with a median age of onset of 47 years. Coronary heart disease was reported in 29% of women with FH, with a median age of onset of 55 years. A high-dose statin was being taken by 42% of individuals with FH, 33% of individuals were on a low-dose statin, and 25% of individuals were not taking a statin. The most common reasons for lack of statin use included intolerance or allergy (60%), patient preference (11%), physician preference (11%), pregnancy (3%), cost (1%), and clinical trial participation (1%). Twenty-five percent of treated individuals had an LDL-C below 100 mg/dL and 41% of individuals achieved a 50% or greater reduction in LDL-C from untreated values [<a class="bk_pop" href="#hyperchol.REF.degoma.2016.240">deGoma et al 2016</a>].</p><p><b>Xanthomas</b> are patches of yellowish cholesterol buildup in particular areas of the body as a result of extremely high levels of LDL-C. Xanthomas may worsen with age in persons who are not treated. In persons treated with LDL-C-lowering therapy, the xanthomas can become smaller. Common locations:</p><ul><li class="half_rhythm"><div>Xanthomas often occur around the eyelids (xanthelasma palpebrarum or more commonly just xanthelasma) [<a class="bk_pop" href="#hyperchol.REF.dey.2013.932863">Dey et al 2013</a>].</div></li><li class="half_rhythm"><div>Tendonous xanthomas can occur in the elbows, hands, knees, and feet, particularly the Achilles tendon [<a class="bk_pop" href="#hyperchol.REF.tsouli.2005.236">Tsouli et al 2005</a>, <a class="bk_pop" href="#hyperchol.REF.elis.2011.223">Elis et al 2011</a>]. These are historically described in 30%-50% of persons with FH, although more recent studies show a lower prevalence likely due to widespread statin use [<a class="bk_pop" href="#hyperchol.REF.perez_de_isla.2016.1278">Perez de Isla et al 2016</a>].</div></li><li class="half_rhythm"><div>Interdigital xanthomas (between the fingers) occur in individuals with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> FH.</div></li></ul><p><b>Corneal arcus</b> (white, gray, or blue opaque ring in the corneal margin). Because corneal arcus becomes increasingly common in the general population with age, it is only diagnostic in younger individuals, particularly before age 45 years.</p></div><div id="hyperchol.Homozygous_Familial_Hyperchole"><h4>Homozygous Familial Hypercholesterolemia (HoFH)</h4><p>Homozygous <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia refers to familial hypercholesterolemia resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in one of the genes listed in <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="fighypercholTmoleculargenetictestingus" rid-ob="figobhypercholTmoleculargenetictestingus">Table 1</a> (<i>APOB</i>, <i>LDLR</i>, and <i>PCSK9</i>). The prevalence of HoFH, estimated at 1:160,000 to 1:250,000, is much lower than FH [<a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>, <a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</a>].</p><p>In adults with HoFH, untreated LDL-C levels are generally, but not always, &#x0003e;500 mg/dL (&#x0003e;13 mmol/L). Levels can be lower in children or in treated individuals. Thus, LDL-C levels are not sufficient to confirm a diagnosis [<a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</a>].</p><p>In addition to xanthomas around the eyelids and tendonous xanthomas, individuals with HoFH can have interdigital xanthomas (between the fingers).</p><p>The natural history of HoFH differs from that of FH. Most individuals with HoFH experience severe CAD by their mid-20s. The rate of either death or coronary bypass surgery by the teenage years is high [<a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>]. Severe aortic stenosis is also common [<a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>, <a class="bk_pop" href="#hyperchol.REF.raal.2016a.238">Raal et al 2016a</a>, <a class="bk_pop" href="#hyperchol.REF.raal.2016b.1458">Raal et al 2016b</a>].</p><p>Statins are often relatively ineffective in the treatment of HoFH because their efficacy largely depends on the upregulation of functional LDL receptors in the liver. In individuals with HoFH, activity of both copies of the LDL receptor are absent or greatly reduced [<a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>]; therefore, therapy for HoFH often requires LDL apheresis in addition to the use of multiple other medications (see <b>Management</b>, <a href="#hyperchol.Treatment_of_Manifestations">Treatment of Manifestations</a>) [<a class="bk_pop" href="#hyperchol.REF.raal.2010.998">Raal et al 2010</a>, <a class="bk_pop" href="#hyperchol.REF.raal.2013.7">Raal 2013</a>, <a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</a>].</p></div></div><div id="hyperchol.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p><b><i>APOB</i>.</b> FH caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>APOB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is reported to be less severe than FH caused by a heterozygous pathogenic variant in <i>LDLR</i> or <i>PCSK9</i> [<a class="bk_pop" href="#hyperchol.REF.hopkins.2011">Hopkins et al 2011</a>].</p></div><div id="hyperchol.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b><i>LDLR.</i></b> Complete <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>LDLR</i> generally lead to more severe disease due to higher LDL-C levels [<a class="bk_pop" href="#hyperchol.REF.khera.2016.2578">Khera et al 2016</a>]. Partial loss-of-function variants in <i>LDLR</i> result in less severe disease due to lower LDL-C levels.</p></div><div id="hyperchol.Penetrance"><h3>Penetrance</h3><p><b><i>APOB.</i></b> Penetrance for FH can be incomplete in persons with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>APOB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hyperchol.REF.fahed.2011.23">Fahed &#x00026; Nemer 2011</a>].</p><p><b><i>LDLR.</i></b> Recent findings suggest that only 73% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>LDLR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have an LDL level &#x0003e;130 mg/dL, suggesting lower <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> than previously proposed [<a class="bk_pop" href="#hyperchol.REF.khera.2016.2578">Khera et al 2016</a>].</p><p><b><i>PCSK9</i></b></p><ul><li class="half_rhythm"><div>Penetrance is approximately 90% in persons <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.pcsk9_selected_pathogenic_va/?report=objectonly" target="object" rid-figpopup="fighypercholTpcsk9selectedpathogenicva" rid-ob="figobhypercholTpcsk9selectedpathogenicva">c.381T&#x0003e;A</a> (p.Ser127Arg) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Penetrance in persons <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.pcsk9_selected_pathogenic_va/?report=objectonly" target="object" rid-figpopup="fighypercholTpcsk9selectedpathogenicva" rid-ob="figobhypercholTpcsk9selectedpathogenicva">p.Asp374Tyr</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is high, with FH manifesting at a young age [<a class="bk_pop" href="#hyperchol.REF.naoumova.2005.2654">Naoumova et al 2005</a>].</div></li><li class="half_rhythm"><div>Penetrance for other <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>PCSK9</i> pathogenic variants remains largely unknown [<a class="bk_pop" href="#hyperchol.REF.cariou.2011.258">Cariou et al 2011</a>].</div></li></ul></div><div id="hyperchol.Prevalence"><h3>Prevalence</h3><p>The prevalence of FH in the general population has traditionally been cited as 1:500. However, emerging data suggest that the prevalence of FH is higher in white/European populations, perhaps as common as 1:200 [<a class="bk_pop" href="#hyperchol.REF.benn.2012.3956">Benn et al 2012</a>, <a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>].</p><p>FH is more common (due to founder effects) in several populations (<a class="figpopup" href="/books/NBK174884/table/hyperchol.T.prevalence_of_fh_in_select_p/?report=objectonly" target="object" rid-figpopup="fighypercholTprevalenceoffhinselectp" rid-ob="figobhypercholTprevalenceoffhinselectp">Table 2</a>). Of note, data are limited on prevalence of FH in most African and South Asian/Indian populations.</p><div id="hyperchol.T.prevalence_of_fh_in_select_p" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Prevalence of FH in Select Populations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.prevalence_of_fh_in_select_p/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.prevalence_of_fh_in_select_p_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Population</th><th id="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prevalence</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">General population</td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:250</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">French Canadian&#x000a0;<sup>1</sup></td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:270</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Old Order Amish&#x000a0;<sup>2</sup></td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:10</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Christian Lebanese</td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:85</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tunisia</td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:165</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">South African Afrikaners</td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:72 to 1:100</td></tr><tr><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">South African Ashkenazi Jews</td><td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:67</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.austin.2004.407">Austin et al [2004]</a></p></div></dd><dt>1. </dt><dd><div id="hyperchol.TF.2.1"><p class="no_margin">A common &#x0003e;15-kb (60% of alleles) and an ~5-kb (5% of alleles) <i>LDLR</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> results in a significant increase in LDL-C [<a class="bk_pop" href="#hyperchol.REF.simard.2004.202">Simard et al 2004</a>].</p></div></dd><dt>2. </dt><dd><div id="hyperchol.TF.2.2"><p class="no_margin">Amish individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>APOB</i> p.Arg3500Gln (the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the Amish community) have average LDL-C levels below the suggested minimum for a diagnosis of FH. However, coronary artery calcification and atherosclerosis still occurred in heterozygous Amish individuals with lower average LDL-C levels [<a class="bk_pop" href="#hyperchol.REF.andersen.2016.443">Andersen et al 2016</a>].</p></div></dd></dl></div></div></div></div></div><div id="hyperchol.Genetically_Related_Allelic_Di"><h2 id="_hyperchol_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p><b><i>APOB.</i></b> Homozygous or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>APOB</i> cause <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypobetalipoproteinemia (OMIM <a href="http://omim.org/entry/615558" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615558</a>) characterized by extremely low levels of LDL-C [<a class="bk_pop" href="#hyperchol.REF.burnett.2012.20">Burnett et al 2012</a>].</p><p><b><i>LDLR.</i></b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>LDLR</i>.</p><p><b><i>PCSK9.</i></b> Heterozygous or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>PCSK9</i> cause hypocholesterolemia (reduced blood cholesterol levels). Loss-of-function pathogenic variants lead to an increase in the number of low-density lipoprotein receptors on the surface of liver cells, resulting in quicker than usual removal of LDL-C from the blood and, hence, a reduced risk for coronary heart disease [<a class="bk_pop" href="#hyperchol.REF.cohen.2006.1264">Cohen et al 2006</a>, <a class="bk_pop" href="#hyperchol.REF.pandit.2008.1333">Pandit et al 2008</a>].</p></div><div id="hyperchol.Differential_Diagnosis"><h2 id="_hyperchol_Differential_Diagnosis_">Differential Diagnosis</h2><p>Conditions with <b>clinical findings</b> similar to those of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia (FH) include the following:</p><ul><li class="half_rhythm"><div><b>27-hydroxylase deficiency (</b><a href="/books/n/gene/ctx/"><b>cerebrotendonous xanthomatosis</b></a><b>),</b> which is characterized by xanthomas. Distinguishing features are normal LDL cholesterol (LDL-C) levels and the presence of dementia, ataxia, and cataracts. Biallelic pathogenic variants in <i>CYP27A1</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Hyperlipoproteinemia type III (<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dysbetalipoproteinemia)</b> (OMIM <a href="http://omim.org/entry/107741" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">107741</a>). Clinical features may include xanthomas. Hyperlipoproteinemia type III is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>APOE.</i> Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> [<a class="bk_pop" href="#hyperchol.REF.fung.2011.2011">Fung et al 2011</a>].</div></li><li class="half_rhythm"><div><a href="/books/n/gene/stsl/"><b>Sitosterolemia</b></a> (phytosterolemia), which is distinguished by normal or only mildly elevated LDL-C levels. Biallelic pathogenic variants in either <i>ABCG5</i> or <i>ABCG8</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Polygenic hypercholesterolemia.</b>
<a class="bk_pop" href="#hyperchol.REF.talmud.2013.1293">Talmud et al [2013]</a> found that individuals with features suggestive of FH in whom an <i>LDLR</i>, <i>PCSK9</i>, or <i>APOB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was not identified are in fact likely to have <a class="def" href="/books/n/gene/glossary/def-item/polygenic/">polygenic</a> hypercholesterolemia. In this case, individuals have a high genetic risk score for more common LDL-C raising alleles.</div></li><li class="half_rhythm"><div><b>Extremely elevated lipoprotein a</b>
<b>(Lpa)</b> (OMIM <a href="http://omim.org/entry/152200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">152200</a>). Individuals with very high Lpa often have a personal and family history of early-onset CAD and very elevated LDL-C levels [<a class="bk_pop" href="#hyperchol.REF.langsted.2016.577">Langsted et al 2016</a>]. High Lpa levels are also widely appreciated to synergistically increase risk in individuals with FH. The disorder is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner and caused by variants in the number of kringle IV type 2 repeats in <i>LPL</i>.</div></li></ul><p>Conditions with <b>laboratory findings</b> similar to those of FH include the following [<a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>]:</p><ul><li class="half_rhythm"><div><b>Hypercholesterolemia</b> secondary to obesity, diabetes mellitus, hypothyroidism, drugs (e.g., steroids), or kidney disease. Inheritance follows a non-Mendelian pattern.</div></li><li class="half_rhythm"><div><b>Autosomal recessive hypercholesterolemia</b> (OMIM <a href="http://omim.org/entry/603813" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603813</a>) caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LDLRAP1</i>. Persons with biallelic pathogenic variants have LDL-C &#x0003e;400 mg/dL (&#x0003e;10 mmol/L), whereas heterozygotes have normal LDL-C levels.</div></li><li class="half_rhythm"><div><b>Familial combined hyperlipidemia</b>
<b>(FCHL)</b> (OMIM <a href="http://omim.org/entry/144250" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">144250</a>), associated with elevated LDL-C and triglycerides. FCHL is genetically heterogeneous. Only 10%-20% of individuals show elevated levels in childhood (usually in the form of hypertriglyceridemia). FCHL is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner and caused by pathogenic variants in <i>LPL</i> [<a class="bk_pop" href="#hyperchol.REF.brahm.2016.131">Brahm &#x00026; Hegele 2016</a>]. Additional loci have been mapped to <i>APOB</i> and <i>USF1</i> in a minority of families [<a class="bk_pop" href="#hyperchol.REF.naukkarinen.2006.285">Naukkarinen et al 2006</a>, <a class="bk_pop" href="#hyperchol.REF.hegele.2009.4189">Hegele et al 2009</a>].</div></li></ul></div><div id="hyperchol.Management"><h2 id="_hyperchol_Management_">Management</h2><div id="hyperchol.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia (FH) the following evaluations are recommended in adults and children:</p><ul><li class="half_rhythm"><div>Measurement of pre-treatment lipid values and lipoprotein(a) levels when possible</div></li><li class="half_rhythm"><div>Exclusion of concurrent illnesses (kidney disease, acute myocardial infarction, infection) that can affect lipid values</div></li><li class="half_rhythm"><div>Lipid panel including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides</div></li><li class="half_rhythm"><div>Consultation with a lipid specialist or clinician with expertise in FH</div></li><li class="half_rhythm"><div>Recommended in some guidelines: noninvasive imaging modalities in children (e.g., measurement of carotid intima-media thickness) to help inform treatment decisions [<a class="bk_pop" href="#hyperchol.REF.martin.2013">Martin et al 2013</a>]</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hyperchol.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="hyperchol.Adults_with_FH"><h4>Adults with FH</h4><p>All individuals with FH should be considered "high risk" for coronary artery disease (CAD) and should be treated actively to lower cholesterol levels. Note that standard Framingham or other risk classification schemes are not applicable [<a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.hopkins.2011">Hopkins et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.stone.2014.2889">Stone et al 2014</a>]. The most current recommendations (summarized here) for the management of FH used in the United States are from the American Heart Association [<a class="bk_pop" href="#hyperchol.REF.gidding.2015.2167">Gidding et al 2015</a>] (<a href="http://circ.ahajournals.org/content/132/22/2167.long" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) and largely reflect earlier recommendations from the National Lipid Association (NLA).</p><p>For adults, treatment should begin as soon as possible after diagnosis. All adults with FH require diet/lifestyle management, and almost without exception will also require cholesterol-lowering drug therapy.</p><ul><li class="half_rhythm"><div>Risk factors (e.g., smoking, diabetes mellitus, hypertension) are the same in FH as in the general population; aggressive management is required to reduce CAD risk, with special attention to smoking cessation.</div></li><li class="half_rhythm"><div>Regular physical activity, a healthy diet (reduce saturated fat intake, increase intake of soluble fiber to 10-20 g/day), and weight control should be emphasized.</div></li><li class="half_rhythm"><div>Blood pressure should be treated to 140/90mm Hg (or 130/80 mm Hg in those with diabetes mellitus).</div></li><li class="half_rhythm"><div>Low-dose aspirin (75-81 mg/day) should be considered in those at high risk for CAD or stroke.</div></li><li class="half_rhythm"><div>Consider referral to a lipid specialist with expertise in FH if LDL-C concentrations are not reduced with maximal medical therapy. (Note: Although it has not been specified, this recommendation generally pertains to LDL-C levels that cannot be reduced by &#x02265;50% with maximal medical therapy over a 6-month period.)</div></li><li class="half_rhythm"><div>Testing of first-degree and second-degree relatives should be recommended to all individuals with FH (see <a href="#hyperchol.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a>).</div></li><li class="half_rhythm"><div>For adults with FH age 20 years or older, treatment with statins should be initiated to reduce the LDL-C level &#x02265;50% or to &#x0003c;100 mg/dL (&#x0003c;2.6 mmol/L) [<a class="bk_pop" href="#hyperchol.REF.hopkins.2011">Hopkins et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>]. Many guidelines suggest a target LDL-C of &#x0003c;100 mg/dL even in those without known CAD as individuals with FH have had a lifelong burden of high LDL-C [<a class="bk_pop" href="#hyperchol.REF.gidding.2015.2167">Gidding et al 2015</a>].</div></li></ul><p><b>For persons with FH with any of the following CAD risk factors,</b> drug treatment may need to be intensified (see *Note) to achieve more aggressive treatment goals (LDL-C &#x0003c;100 mg/dL [&#x0003c;2.6 mmol/L] and non-HDL-C &#x0003c;130 mg/dL [&#x0003c;3.4 mmol/L]). Risk factors:</p><ul><li class="half_rhythm"><div>Clinically evident CAD or other atherosclerotic cardiovascular disease; the goal is LDL-C level of &#x0003c;70 mg/dL (&#x0003c;1.8 mmol/L)</div></li><li class="half_rhythm"><div>Diabetes mellitus or metabolic syndrome</div></li><li class="half_rhythm"><div>Family history of very early CAD (men age &#x0003c;45 years; women age &#x0003c;55 years)</div></li><li class="half_rhythm"><div>Current smoking</div></li><li class="half_rhythm"><div>High lipoprotein(a) (&#x02265;50 mg/dL [&#x02265;1.3 mmol/L] using an isoform insensitive assay)</div></li></ul><p>The second-line agent for individuals with FH who do not achieve acceptable LDL-C levels is generally ezetimibe. Treatment options for intensification of therapy after ezetimibe or for those intolerant of statins include bile acid sequestrants and/or PCSK9 inhibitors. Although niacin has been used as an adjunctive therapy in individuals with FH, given recent data, niacin is generally not favored before the other options have been exhausted [<a class="bk_pop" href="#hyperchol.REF.guyton.2013.1580">Guyton et al 2013</a>, <a class="bk_pop" href="#hyperchol.REF28">FDA 2016</a>] (see <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.current_recommended_drug_the/?report=objectonly" target="object" rid-figpopup="fighypercholTcurrentrecommendeddrugthe" rid-ob="figobhypercholTcurrentrecommendeddrugthe">Table 3</a>).</p><p><b>In persons with FH without any of the CAD risk factors</b> listed above, intensification of drug therapy (see *Note) should be strongly considered if 50% reduction in LDL-C is not achieved after six months on maximum statin therapy. For adults, some guidelines call for intensification of treatment if the goal LDL-C of &#x0003c;100 mg/dL (&#x0003c;2.6 mmol/L) is not achieved [<a class="bk_pop" href="#hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</a>].</p><p>*Note: (1) The lipid-lowering therapy should initially be statin-based with titration of doses every few months in order to use the highest tolerated dose of a potent statin, followed by addition of other drugs if the targeted LDL-C level is not achieved. (2) The potential benefit of multidrug regimens should be weighed against the increased cost and potential for adverse effects and decreased adherence.</p><div id="hyperchol.T.current_recommended_drug_the" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Current Recommended Drug Therapies for Adults with FH</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.current_recommended_drug_the/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.current_recommended_drug_the_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Class</th><th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primary (1<sup>O</sup>) and Secondary (2<sup>O</sup>) Mechanism of Action</th><th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LDL-Lowering Response</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Statins</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; LDLR activity (1<sup>O</sup>)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;35%&#x000a0;<sup>1,&#x000a0;2</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cholesterol absorption inhibitors (ezetimibe)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; Cholesterol absorption (1<sup>O</sup>)<br />&#x02191; LDLR activity (2<sup>O</sup>)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%&#x000a0;<sup>1,&#x000a0;3</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mipomersen (APOB antisense)&#x000a0;<sup>4</sup></td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blocks APOB production in the liver</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MTP inhibitor<br />(lomitapide)&#x000a0;<sup>4</sup></td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; microsomal triglyceride transfer protein activity&#x000a0;(1<sup>O</sup>)<br />Inhibition of LDL production (2<sup>O</sup>)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PCSK9 inhibitors<br />(alirocumab, evolocumab)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; LDL-receptor degradation</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bile acid sequestrants<br />(cholestyramine, colesevelam)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; Bile acid reabsorption (1<sup>O</sup>)<br />&#x02191; LDLR activity (2<sup>O</sup>)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%&#x000a0;<sup>1,&#x000a0;3</sup></td></tr><tr><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stanol esters</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; Cholesterol absorption (1<sup>O</sup>)<br />&#x02191; LDLR activity (2<sup>O</sup>)</td><td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%&#x000a0;<sup>1,&#x000a0;3</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Some guidelines call for the addition of n-3 polyunsaturated fatty acids or fibrates if triglycerides remain elevated after the LDL-C is controlled.</p></div></dd><dt>1. </dt><dd><div id="hyperchol.TF.3.1"><p class="no_margin">Often ineffective in HoFH</p></div></dd><dt>2. </dt><dd><div id="hyperchol.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.kastelein.2008.1431">Kastelein et al [2008]</a></p></div></dd><dt>3. </dt><dd><div id="hyperchol.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.rader.2003.1795">Rader et al [2003]</a></p></div></dd><dt>4. </dt><dd><div id="hyperchol.TF.3.4"><p class="no_margin">Approved only for adults with HoFH</p></div></dd><dt>5. </dt><dd><div id="hyperchol.TF.3.5"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al [2014]</a></p></div></dd><dt>6. </dt><dd><div id="hyperchol.TF.3.6"><p class="no_margin"><a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos [2012]</a></p></div></dd></dl></div></div></div></div><div id="hyperchol.Children_with_FH"><h4>Children with FH</h4><p>Guidelines for the management of children and individuals up to age 21 years have been published by the National Heart, Lung, and Blood Institute (<a href="https://www.nhlbi.nih.gov/files/docs/peds_guidelines_sum.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). Children should be considered for drug treatment with statin-based regimens when:</p><ul><li class="half_rhythm"><div>LDL-C levels are &#x02265;190 mg/dL (&#x02265;4.9 mmol/L).</div></li><li class="half_rhythm"><div>LDL-C levels are &#x02265;160 mg/dL (&#x02265;4.1 mmol/L) and at least two other risk factors are present.</div></li></ul><p>US-based guidelines from the NLA (<a href="https://www.lipid.org/sites/default/files/articles/familial_hypercholesterolemia_1.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>):</p><ul><li class="half_rhythm"><div>Consultation or referral to a lipid specialist is recommended.</div></li><li class="half_rhythm"><div>Management of diet and physical activity is recommended at an early age.</div></li><li class="half_rhythm"><div>Statins are the preferred initial pharmacologic treatment in children. Consideration should be given to starting statin treatment at age eight years or older. In special cases, such as children with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> FH, drug treatment needs to be initiated prior to age eight years.</div></li><li class="half_rhythm"><div>The goal of lipid-lowering therapy in children with FH is a &#x02265;50% reduction in LDL-C or LDL-C &#x0003c;130 mg/dL (&#x0003c;3.4 mmol/L). Note: More aggressive lowering of LDL-C levels should be considered for children with additional CAD risk factors (e.g., family history of CAD, high blood pressure, unhealthy diet or exercise behaviors, obesity).</div></li></ul></div><div id="hyperchol.Children_and_Adults_with_Homoz"><h4>Children and Adults with Homozygous FH (HoFH)</h4><p>NLA guidelines for <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> FH (<a href="https://www.lipid.org/sites/default/files/articles/familial_hypercholesterolemia_1.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>):</p><ul><li class="half_rhythm"><div>Referral to a lipid specialist is indicated.</div></li><li class="half_rhythm"><div>Early initiation of therapy and monitoring are recommended.</div></li><li class="half_rhythm"><div>Multiple drug therapy is usually needed. Several different classes of medications are currently being used to treat HoFH (see <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.current_recommended_drug_the/?report=objectonly" target="object" rid-figpopup="fighypercholTcurrentrecommendeddrugthe" rid-ob="figobhypercholTcurrentrecommendeddrugthe">Table 3</a>).</div></li><li class="half_rhythm"><div>Since many cholesterol-lowering medications target the LDL receptor, effectiveness in persons with FH with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> loss-of function <i>LDLR</i> pathogenic variants can be limited [<a class="bk_pop" href="#hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</a>]. Statins are often relatively ineffective in the treatment of HoFH because their efficacy largely depends on the upregulation of functional LDL receptors in the liver. In HoFH, both copies of the LDL receptor have absent or greatly reduced activity [<a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>].</div></li><li class="half_rhythm"><div>High-dose statins, ezetimibe, and bile-acid binding resins may be effective in some persons with HoFH, especially those with some residual LDLR activity.</div></li><li class="half_rhythm"><div>For HoFH, evolocumab is a PCSK9 inhibitor that showed a 40% mean reduction in LDL-C compared with placebo; however, individuals with two <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants saw no response [<a class="bk_pop" href="#hyperchol.REF.raal.2015.341">Raal et al 2015</a>]. PCSK9 inhibitors have not been formally approved in children with FH.</div></li><li class="half_rhythm"><div>HoFH-specific medications (lomitapide and mipomersen) are effective even with complete loss of LDL receptor function and &#x02013; though not formally FDA approved for children &#x02013; should strongly be considered.</div></li><li class="half_rhythm"><div>Despite these options, many individuals with HoFH (especially those with complete loss of LDL receptor function) will require ongoing LDL apheresis. LDL apheresis (&#x02264;2x/week) is often required starting from a young age. Apheresis can lower LDL-C levels by 80% acutely and 30% chronically (weekly or biweekly). Apheresis is offered at a limited number (~40-50) of centers in the United States; many states do not have an apheresis center.</div></li><li class="half_rhythm"><div>Liver transplantation is also being used in rare circumstances in some centers [<a class="bk_pop" href="#hyperchol.REF.martinez.2016.504">Martinez et al 2016</a>]</div></li></ul></div></div><div id="hyperchol.Prevention_of_Primary_Manifest"><h3>Prevention of Primary Manifestations</h3><p>Preventive measures include the following:</p><ul><li class="half_rhythm"><div>Statin-based therapy with addition of other medications as needed</div></li><li class="half_rhythm"><div>Reduced intake of saturated fat</div></li><li class="half_rhythm"><div>Increased intake of soluble fiber to 10-20 g/day</div></li><li class="half_rhythm"><div>Increased physical activity</div></li><li class="half_rhythm"><div>Not smoking</div></li></ul></div><div id="hyperchol.Surveillance"><h3>Surveillance</h3><p><b>Children.</b> Guidelines for the management of children have been published by multiple national and international organizations [<a class="bk_pop" href="#hyperchol.REF.daniels.2008">Daniels et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.demott.2008">DeMott et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.descamps.2011">Descamps et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.martin.2013">Martin et al 2013</a>] (see <a href="#hyperchol.References">Published Guidelines / Consensus Statements</a>).</p><p>A child who has a family history of FH or of premature CAD, who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the FH <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in his or her family, or who has an elevated serum cholesterol concentration should have lipid levels checked starting as early as age two years [<a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>]. It is reasonable to check a non-fasting lipid level first and, if borderline, to follow with measurement of LDL-C. Some guidelines state that elevation of two consecutive measures of LDL-C are needed to confirm a diagnosis of FH [<a class="bk_pop" href="#hyperchol.REF.martin.2013">Martin et al 2013</a>].</p><p>An LDL-C level of &#x0003e;130 mg/dL (&#x0003e;3.4 mmol/L) in a child is suspicious for FH and an LDL of &#x0003e;160 mg/dL (&#x0003e;4.1 mmol/L) is relatively specific for FH.</p><p><b>During treatment, individuals of any age</b> with:</p><ul><li class="half_rhythm"><div><b>FH</b> should have lipid levels monitored as recommended;</div></li><li class="half_rhythm"><div><b>HoFH</b> should be monitored with various imaging modalities (including echocardiogram, CT angiogram, and cardiac catheterization) as recommended [<a class="bk_pop" href="#hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</a>].</div></li></ul></div><div id="hyperchol.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Smoking</div></li><li class="half_rhythm"><div>High intake of saturated and trans unsaturated fat</div></li><li class="half_rhythm"><div>Excessive intake of cholesterol</div></li><li class="half_rhythm"><div>Sedentary lifestyle</div></li><li class="half_rhythm"><div>Obesity</div></li><li class="half_rhythm"><div>Hypertension</div></li><li class="half_rhythm"><div>Diabetes mellitus</div></li></ul></div><div id="hyperchol.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>The CDC has classified FH as a Tier 1 condition indicating a significant benefit from performing family-based cascade screening using cholesterol testing with or without DNA analysis on relatives of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons with FH in order to identify previously unknown cases of FH and provide those people with lifesaving treatment. Early diagnosis and treatment of relatives at risk for FH can reduce morbidity and mortality [<a class="bk_pop" href="#hyperchol.REF.goldberg.2011">Goldberg et al 2011</a>, <a class="bk_pop" href="#hyperchol.REF.ned.2011.rrn1238">Ned &#x00026; Sijbrands 2011</a>, <a class="bk_pop" href="#hyperchol.REF.reiner.2011.1769">Reiner et al 2011</a>].</p><p>The genetic status of at-risk family members can be clarified by EITHER of the following:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member</div></li><li class="half_rhythm"><div>Measurement of LDL-C level. <a class="figpopup" href="/books/NBK174884/table/hyperchol.T.total_and_ldl_cholesterol_le/?report=objectonly" target="object" rid-figpopup="fighypercholTtotalandldlcholesterolle" rid-ob="figobhypercholTtotalandldlcholesterolle">Table 4</a> provides age-specific total cholesterol and LDL-C levels [<a class="bk_pop" href="#hyperchol.REF.williams.1993.319s">Williams et al 1993</a>]. Note: Age-specific LDL cut-offs are also available based on more contemporary data from the United Kingdom [<a class="bk_pop" href="#hyperchol.REF.starr.2008.791">Starr et al 2008</a>].</div></li></ul><div id="hyperchol.T.total_and_ldl_cholesterol_le" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Total and LDL Cholesterol Levels in Heterozygotes for FH Based on Degree of Relatedness to an Individual with FH</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.total_and_ldl_cholesterol_le/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.total_and_ldl_cholesterol_le_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Degree of Relatedness to an Affected Individual</th><th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">First Degree&#x000a0;<sup>1</sup></th><th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Second Degree&#x000a0;<sup>2</sup></th><th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Third Degree&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1" id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Cholesterol Levels</th><th headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4" id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Total Cholesterol (LDL Cholesterol) in mg/dL</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Age</b></td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;20</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">220 (155)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">230 (165)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">240 (170)</td></tr><tr><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">20-29</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">240 (170)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 (180)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">260 (185)</td></tr><tr><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">30-39</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">270 (190)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">280 (200)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">290 (210)</td></tr><tr><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">40+</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">290 (205)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">300 (215)</td><td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">310 (225)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hyperchol.TF.4.1"><p class="no_margin">A parent, sib, or child. First-degree relatives share about half of their genes.</p></div></dd><dt>2. </dt><dd><div id="hyperchol.TF.4.2"><p class="no_margin">An uncle, aunt, nephew, niece, grandparent, grandchild, or half-sib. Second-degree relatives share about one quarter of their genes.</p></div></dd><dt>3. </dt><dd><div id="hyperchol.TF.4.3"><p class="no_margin">A first cousin, great-grandparent, or great-grandchild. Third-degree relatives share about one eighth of their genes.</p></div></dd></dl></div></div></div><p>Of note, all national and international guidelines for FH call for "cascade testing" of relatives at risk (i.e., systematic testing of first- and second-degree relatives of the index case [<a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>]). Evidence supports the use of genetic testing in cascade testing algorithms to improve the detection of FH [<a class="bk_pop" href="#hyperchol.REF.demott.2008">DeMott et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.wierzbicki.2008.a1095">Wierzbicki et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.wald.2016.1628">Wald et al 2016</a>].</p><p>See <a href="#hyperchol.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hyperchol.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Statins are contraindicated during pregnancy; women with FH who are considering a pregnancy should be counseled of this risk and statins should be discontinued prior to conception.</p><p>Pregnant women should incorporate all the other recommended lifestyle changes including low saturated and trans unsaturated fat intake, no smoking, and high dietary soluble fiber intake (see <a href="#hyperchol.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</p><p><b>Pharmacologic treatment</b>
<b>during pregnancy</b></p><ul><li class="half_rhythm"><div>Statins are contraindicated in pregnancy due to concerns for teratogenicity. The use of statins during human pregnancy has not definitively been associated with adverse fetal outcome; however, the role of cholesterol in embryologic development has led to theoretic concerns about the effect of these medications on a developing fetus and a recommendation that alternative medications be considered during pregnancy and lactation. Nursing mothers should not take statins.</div></li><li class="half_rhythm"><div>Bile acid binding resins (colesevelam, cholestyramine) are generally considered safe (Class B for pregnancy). Based primarily on animal studies, cholestyramine use during pregnancy has not been associated with an increased risk of fetal anomalies. However, use of cholestyramine could theoretically cause depletion of maternal fat-soluble vitamins, including vitamin K.</div></li><li class="half_rhythm"><div>LDL apheresis is also occasionally used.</div></li><li class="half_rhythm"><div>Regarding other agents:</div><ul><li class="half_rhythm"><div>PCSK9 inhibitors. Use during pregnancy has not been well studied.</div></li><li class="half_rhythm"><div>Ezetimibe. Use during human pregnancy has not been well studied.</div></li><li class="half_rhythm"><div>Niacin. The use of pharmacologic doses of niacin, an essential vitamin, has not been studied in human pregnancy. The recommended upper limit of niacin intake during pregnancy is 30-35 mgs/day; higher doses have been associated with toxicity.</div></li></ul></li></ul></div><div id="hyperchol.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>CAD outcome trials of PCSK9 inhibitors are currently underway.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="hyperchol.Genetic_Counseling"><h2 id="_hyperchol_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hyperchol.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia (FH, HeFH) and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> familial hypercholesterolemia (HoFH) are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hyperchol.Risk_to_Family_Members"><h3>Risk to Family Members</h3><div id="hyperchol.Heterozygous_Familial_Hypercho"><h4>Heterozygous Familial Hypercholesterolemia (FH)</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Almost all individuals diagnosed with FH have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with FH may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Because <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) have not yet been evaluated sufficiently to determine if the pathogenic variant occurred <i>de novo</i>, the proportion of FH caused by <i>de novo</i> pathogenic variants is unknown but appears to be very low.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variant has been identified in the proband, or cholesterol testing if the pathogenic variant has not been identified in the proband. Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li><li class="half_rhythm"><div>Note: Although most individuals diagnosed with FH have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If both parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with FH or have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to sibs of having FH is 50%, the risk to sibs having HoFH is 25%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be very low.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent. However, this is a very unlikely scenario.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with FH has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If both parents of a child are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with FH, the child has a 50% chance of having FH and a 25% chance of having HoFH.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents. If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband, the pathogenic variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p></div><div id="hyperchol.Homozygous_Familial_Hyperchole_1"><h4>Homozygous Familial Hypercholesterolemia (HoFH)</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes and thus have one <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Individuals with one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have FH.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs of having FH is 50%; the risk to sibs of having HoFH is 25%.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with HoFH are obligate heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; thus, all will have FH.</p><p><b>Other family members.</b> Sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents are at 50% risk of having a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and, thus, FH.</p></div></div><div id="hyperchol.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hyperchol.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Specific risk issues.</b> Individuals inheriting pathogenic variants from both parents will develop a severe form of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercholesterolemia (HoFH).</p><p><b>Predictive genetic testing</b> for asymptomatic adult family members at risk for FH requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hyperchol.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in a family member with FH (or both pathogenic variants have been identified in a family member with HoFH), prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hyperchol.Resources"><h2 id="_hyperchol_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>British Heart Foundation</b></div><div><a href="http://www.bhf.org.uk/heart-health/conditions/familial-hypercholesterolaemia.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial Hypercholesterolaemia</a></div></li><li class="half_rhythm"><div><b>FH Australasia Network</b></div><div>AAS Secretariat</div><div><b>Phone:</b> 61 3 5967 4479</div><div><b>Fax:</b> 61 3 9015 6409</div><div><b>Email:</b> aas@meetingsfirst.com.au</div><div><a href="http://www.athero.org.au/FH/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.athero.org.au/FH</a></div></li><li class="half_rhythm"><div><b>FH Foundation</b></div><div>959 East Walnut Street</div><div>Suite 220</div><div>Pasadena CA 91106</div><div><b>Phone:</b> 626-583-4674 </div><div><b>Email:</b> info@thefhfoundation.org</div><div><a href="https://thefhfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thefhfoundation.org</a></div></li><li class="half_rhythm"><div><b>FH Norway, Norwegian FH Patient Organization</b></div><div><a href="http://www.f-h.no/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.f-h.no</a></div></li><li class="half_rhythm"><div><b>FH Portugal, Portuguese FH Patient Organization</b></div><div><a href="http://www.fhportugal.pt/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fhportugal.pt</a></div></li><li class="half_rhythm"><div><b>FHChol Austria, Austrian FH Patient Organization</b></div><div>Austria</div><div><a href="http://www.fhchol.at/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fhchol.at</a></div></li><li class="half_rhythm"><div><b>Fundaci&#x000f3;n Hipercolesterolemia Familiar</b></div><div>Spain</div><div><b>Phone:</b> 91 504 22 06; 91 557 00 71</div><div><b>Fax:</b> 91 504 22 06</div><div><b>Email:</b> info@colesterolfamiliar.org</div><div><a href="http://www.colesterolfamiliar.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.colesterolfamiliar.org</a></div></li><li class="half_rhythm"><div><b>German FH Patient Organization</b></div><div>Germany</div><div><a href="http://www.cholco.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cholco.org</a></div></li><li class="half_rhythm"><div><b>International FH Foundation</b></div><div>FHchol Austria</div><div>F&#x000fc;rst Liechtensteinstra&#x000df;e 2/9 </div><div> Wien 1230</div><div>Austria</div><div><b>Phone:</b> 0664 653 59 32</div><div><b>Email:</b> info@fhchol.at</div><div><a href="http://www.fhchol.at/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fhchol.at</a></div></li><li class="half_rhythm"><div><b>Make Early Diagnosis Prevent Early Death (MEDPED)</b></div><div><a href="http://www.medped.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.medped.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000392.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial hypercholesterolemia</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Familial%20Hypercholesterolemia&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial Hypercholesterolemia</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hypercholesterolemia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hypercholesterolemia</a></div></li><li class="half_rhythm"><div><b>Preventive Cardiovascular Nurses Association</b></div><div>PCNA National Office</div><div>613 Williamson Street</div><div>Suite 200</div><div>Madison WI 53703</div><div><b>Phone:</b> 608-250-2440</div><div><a href="http://pcna.net/patients/familial-hypercholesterolemia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pcna.net</a></div></li><li class="half_rhythm"><div><b>HEART UK</b></div><div>United Kingdom</div><div><b>Phone:</b> 0845 450 5988</div><div><b>Email:</b> ask@heartuk.org.uk</div><div><a href="http://heartuk.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.heartuk.org.uk</a></div></li><li class="half_rhythm"><div><b>Japan Atherosclerosis Society</b></div><div>Japan</div><div><a href="http://www.j-athero.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.j-athero.org</a></div></li><li class="half_rhythm"><div><b>Learn Your Lipids</b></div><div><a href="http://www.learnyourlipids.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.learnyourlipids.com</a></div></li><li class="half_rhythm"><div><b>National Lipid Association (NLA)</b></div><div>6816 Southpoint Parkway</div><div>Suite 1000</div><div>Jacksonville FL 32216</div><div><b>Phone:</b> 904-998-0854</div><div><b>Fax:</b> 904-998-0855</div><div><a href="http://www.lipid.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.lipid.org</a></div></li><li class="half_rhythm"><div><b>CASCADE FH Registry</b></div><div><a href="http://thefhfoundation.org/registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thefhfoundation.org/registry</a></div></li></ul></div><div id="hyperchol.Molecular_Genetics"><h2 id="_hyperchol_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hyperchol.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Familial Hypercholesterolemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hyperchol.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hyperchol.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hyperchol.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hyperchol.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hyperchol.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hyperchol.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hyperchol.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/338" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>APOB</i></a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=338" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p24<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P04114" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Apolipoprotein B-100</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/APOB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APOB database</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=APOB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APOB</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=APOB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APOB</a></td></tr><tr><td headers="hd_b_hyperchol.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3949" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LDLR</i></a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3949" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01130" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Low-density lipoprotein receptor</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/LDLR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LDLR @ LOVD</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LDLR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LDLR</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LDLR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LDLR</a></td></tr><tr><td headers="hd_b_hyperchol.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/255738" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PCSK9</i></a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=255738" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p32<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8NBP7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Proprotein convertase subtilisin/kexin type 9</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/PCSK9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PCSK9 @ LOVD</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PCSK9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PCSK9</a></td><td headers="hd_b_hyperchol.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PCSK9[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PCSK9</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hyperchol.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hyperchol.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Familial Hypercholesterolemia (<a href="/omim/107730,143890,144010,603776,606945,607786" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/107730" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">107730</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">APOLIPOPROTEIN B; APOB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/143890" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">143890</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPERCHOLESTEROLEMIA, FAMILIAL, 1; FHCL1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/144010" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">144010</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPERCHOLESTEROLEMIA, FAMILIAL, 2; FCHL2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603776" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603776</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPERCHOLESTEROLEMIA, FAMILIAL, 3; FHCL3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606945" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606945</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607786" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607786</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 9; PCSK9</td></tr></tbody></table></div></div><p><b><i>APOB</i></b></p><p><b>Gene structure.</b>
<i>APOB</i> is 42,216 base pairs in length, comprising 28 introns and 29 exons. It has an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> of 13,692 bases.</p><p>The distribution of the introns within the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is unusual in that 24 of the 29 introns occur in the 5' terminus. More than half of the protein is coded by the 7,572-bp <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 26, one of the largest exons reported in the human genome. One of the two main <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, apoB-100, synthesized exclusively in the liver, is responsible for complications related to FH [<a class="bk_pop" href="#hyperchol.REF.whitfield.2004.1725">Whitfield et al 2004</a>]. For a detailed summary of gene and protein information, see <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than five pathogenic variants have been reported to be associated with FH, two of which are repeatedly found to be significant:</p><ul><li class="half_rhythm"><div>p.Arg3527Gln, found mainly in people with European ancestry</div></li><li class="half_rhythm"><div>p.Arg3527Trp, which tends to be found mostly within Asian populations [<a class="bk_pop" href="#hyperchol.REF.calandra.2011.1885">Calandra et al 2011</a>]</div></li></ul><p>Pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> account for approximately 1%-5% of all persons with FH.</p><p>See also <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>ClinVar</b>.</p><div id="hyperchol.T.apob_selected_pathogenic_var" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>APOB</i> Selected Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.apob_selected_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.apob_selected_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10580G&#x0003e;A&#x000a0;<sup>2</sup><br />(9775G&#x0003e;A)</td><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg3527Gln<br />(Arg3500Gln)</td><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000384.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000384<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000375.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000375<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10579C&#x0003e;T<br />(9774C&#x0003e;T)</td><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg3527Trp<br />(Arg3500Trp)</td></tr><tr><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10672C&#x0003e;T</td><td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg3558Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">Amino acids are numbered from the beginning of the protein precursor, including signal sequence, and nucleotides from first base of the ATG initiation codon.</p></div></dd><dt>1. </dt><dd><div id="hyperchol.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions. In this case, numbering is based on mature peptide before cleavage of signal peptide and corresponding nucleotides.</p></div></dd><dt>2. </dt><dd><div id="hyperchol.TF.5.2"><p class="no_margin"><a href="http://uswest.ensembl.org/Homo_sapiens/Variation/Summary?r=2:21228660-21229660;toggle_HGVS_names=open;v=rs5742904;vdb=variation;vf=3917324" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs5742904</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene product is the main apolipoprotein of chylomicrons and low-density lipoproteins. Human <i>APOB</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is 14.5 kb in length and codes for a mature protein of 4,560 amino acids [<a href="http://genome.ucsc.edu/cgi-bin/hgGene?hgg_gene=uc002red.3&#x00026;hgg_prot=NP_000375&#x00026;hgg_chrom=chr2&#x00026;hgg_start=21224300&#x00026;hgg_end=21266945&#x00026;hgg_type=knownGene&#x00026;db=hg19&#x00026;hgsid=341540851" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UCSC Genome Browser, <i>APOB</i></a>; accessed July 10, 2013].</p><p><i>APOB</i> has four functional domains [<a class="bk_pop" href="#hyperchol.REF.innerarity.1990.1337">Innerarity et al 1990</a>]:</p><ul><li class="half_rhythm"><div>Synthesis, assembly, and secretion of hepatic triglyceride-rich lipoproteins</div></li><li class="half_rhythm"><div>Binding of lipids and serving as a structural component of very low-density lipoproteins (VLDL) and LDL</div></li><li class="half_rhythm"><div>Binding of heparin and various proteoglycans found in the arterial wall</div></li><li class="half_rhythm"><div>Interaction with the LDL receptor, important for clearance of LDL from plasma</div></li></ul><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>APOB</i> is generally involved in aiding the binding of LDL-C to its receptor on the cell surface. <i>APOB</i> pathogenic variants alter the ability of protein to effectively bind LDL-C to <i>LDLR</i>, causing fewer LDL-C particles to be removed from the blood.</p><p><b><i>LDLR</i></b></p><p><b>Gene structure.</b>
<i>LDLR</i> spans 45 kb, comprising 18 exons and 17 introns. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants have been reported in the promoter, introns, and exons of <i>LDLR</i>. The majority of pathogenic variants fall within the ligand-binding (40%) or epidermal growth factor precursor-like (47%) domains, with the highest frequency of pathogenic variants reported in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 (20%) [<a class="bk_pop" href="#hyperchol.REF.leigh.2008.485">Leigh et al 2008</a>, <a class="bk_pop" href="#hyperchol.REF.usifo.2012.387">Usifo et al 2012</a>]. More than 1,500 <i>LDLR</i> pathogenic variants have been reported in the University College London (UCL) database, highlighting the molecular heterogeneity of the disorder. See <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>ClinVar</b>, for a list of reported variants.</p><div id="hyperchol.T.ldlr_selected_pathogenic_var" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>LDLR</i> Selected Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.ldlr_selected_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.ldlr_selected_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;15-kb del&#x000a0;<sup>1</sup><br />(5' of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> through <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1)</td><td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000527.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000527<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000518.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000518<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5-kb del&#x000a0;<sup>1</sup><br />(<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 2 and 3)</td><td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hyperchol.TF.6.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>LDLR</i> encodes a mature protein product of 839 amino acids [<a href="/protein/NP_000518.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000518.1</a>]. LDLR has four distinct functional domains that can function independently of each other [<a href="/Structure/cdd/wrpsb.cgi?seqinput=NP_001182729.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCBI Conserved LDLR Domains</a>; accessed July 10, 2013]:</p><ul><li class="half_rhythm"><div>LDL receptor <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> class A (LDLa)</div></li><li class="half_rhythm"><div>Epidermal growth factor-like <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (EGF)</div></li><li class="half_rhythm"><div>Calcium-binding EGF-like <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (EGF-CA)</div></li><li class="half_rhythm"><div>LDL receptor repeat class B (LDLb)</div></li></ul><p>LDLR consists of cell surface proteins involved in endocytosis of LDL cholesterol (LDL-C). After LDL-C is bound at the cell membrane, it is taken into the cell and to lysosomes where the protein moiety is degraded and the cholesterol molecule suppresses cholesterol synthesis via negative feedback.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>LDLR</i> usually either reduce the number of LDL receptors produced within the cells or disrupt the ability of the receptor to bind LDL-C. Either way, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>LDLR</i> cause high levels of plasma LDL-C [<a href="http://genome.ucsc.edu/cgi-bin/hgGene?hgg_gene=uc002mqk.4&#x00026;hgg_prot=P01130&#x00026;hgg_chrom=chr19&#x00026;hgg_start=11200037&#x00026;hgg_end=11244505&#x00026;hgg_type=knownGene&#x00026;db=hg19&#x00026;hgsid=341540851" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UCSC Genome Browser, LDLR</a>; accessed July 10, 2013].</p><p><b><i>PCSK9</i></b></p><p><b>Gene structure.</b>
<i>PCSK9</i> has a transcript size of 25,378 bp and 12 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Approximately 100 variants in <i>PCSK9</i> have been submitted to the University College London database [<a class="bk_pop" href="#hyperchol.REF.abifadel.2003.154">Abifadel et al 2003</a>]. Although many are hypothesized to be pathogenic, few have been consistently and significantly associated with FH [<a class="bk_pop" href="#hyperchol.REF.naoumova.2005.2654">Naoumova et al 2005</a>]. For a complete list of reported variants, see <a href="/books/NBK174884/#hyperchol.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>ClinVar</b>.</p><div id="hyperchol.T.pcsk9_selected_pathogenic_va" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p><i>PCSK9</i> Selected Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK174884/table/hyperchol.T.pcsk9_selected_pathogenic_va/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hyperchol.T.pcsk9_selected_pathogenic_va_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.381T&#x0003e;A</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser127Arg</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_174936.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_174936<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_777596.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_777596<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.644G&#x0003e;A</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg215His</td></tr><tr><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.646T&#x0003e;C</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe216Leu</td></tr><tr><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1120G&#x0003e;T</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp374Tyr</td></tr><tr><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1486C&#x0003e;T</td><td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg496Trp</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PCSK9</i> encodes a protein consisting of 692 amino acids and three main domains:</p><ul><li class="half_rhythm"><div>Prodomain</div></li><li class="half_rhythm"><div>Catalytic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a></div></li><li class="half_rhythm"><div>C-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a></div></li></ul><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <i>PCSK9</i> protein product binds to LDL lipid receptors and promotes their degradation in intracellular acidic compartments.</p><p>Pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been associated both with hypercholesterolemia and hypocholesterolemia.</p><ul><li class="half_rhythm"><div>Gain-of-function pathogenic variants cause hypercholesterolemia by excessive degradation of LDLRs, reducing the amount of LDL-C removed from the blood.</div></li><li class="half_rhythm"><div>Loss-of-function pathogenic variants cause hypocholesterolemia (reduced blood cholesterol levels) by increasing the number of LDLRs on the surface of liver cells, resulting in a quicker than usual removal of LDL-C from the blood and reduced incidence of coronary artery disease [<a class="bk_pop" href="#hyperchol.REF.cohen.2006.1264">Cohen et al 2006</a>, <a class="bk_pop" href="#hyperchol.REF.pandit.2008.1333">Pandit et al 2008</a>].</div></li></ul></div><div id="hyperchol.References"><h2 id="_hyperchol_References_">References</h2><div id="hyperchol.Published_Guidelines__Consensu"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF1">American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Available <a href="http://www.sciencedirect.com/science/article/pii/S0022522311011287" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 10-21-19. [<a href="/pubmed/22068435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22068435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.daniels.2008">Daniels SR, Greer FR; Committee on Nutrition. 2008. Lipid screening and cardiovascular health in childhood. Available <a href="http://pediatrics.aappublications.org/content/122/1/198.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2008. Accessed 10-21-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.demott.2008">DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical guidelines and evidence review for familial hypercholesterol&#x000e6;mia: the identification and management of adults and children with familial hypercholesterol&#x000e6;mia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. Available <a href="/books/NBK53822/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2008. Accessed 10-21-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.descamps.2011">Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G, Heller FR. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, p&#x000e6;diatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. 2011. [<a href="/pubmed/21762914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21762914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.goldberg.2011">Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011. [<a href="/pubmed/21600525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21600525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.hopkins.2011">Hopkins PN, Toth PP, Ballantyne CM, Rader DJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011. [<a href="/pubmed/21600530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21600530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.ito.2011">Ito MK, McGowan MP, Moriarty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011. [<a href="/pubmed/21600528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21600528</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.martin.2013">Martin AC, Coakley J, Forbes DA, Sullivan DR, Watts GF. Familial hypercholesterol&#x000e6;mia in children and adolescents: a new p&#x000e6;diatric model of care. 2013. [<a href="/pubmed/23252991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23252991</span></a>]</div></li></ul></div><div id="hyperchol.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.abifadel.2003.154">Abifadel M, Varret M, Rab&#x000e8;s JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derr&#x000e9; A, Vill&#x000e9;ger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">34</span>:154–6.</span> [<a href="/pubmed/12730697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12730697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.andersen.2016.443">Andersen L, Ibarra J, Andersen R. Current familial hypercholesterolemia diagnostic criteria underdiagnose APOB mutations: lessons from the Amish community. <span><span class="ref-journal">J Clin Lipidol. </span>2016;<span class="ref-vol">10</span>:443–4.</span> [<a href="/pubmed/27055977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27055977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.austin.2004.407">Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. <span><span class="ref-journal">Am J Epidemiol. </span>2004;<span class="ref-vol">160</span>:407–20.</span> [<a href="/pubmed/15321837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15321837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.awan.2013.218">Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, Gagnon MH, Wang RH, Peloso GM, Hegele RA, Seidah NG, Kathiresan S, Genest J. APOE p.Leu167del mutation in familial hypercholesterolemia. <span><span class="ref-journal">Atherosclerosis. </span>2013;<span class="ref-vol">231</span>:218–22.</span> [<a href="/pubmed/24267230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24267230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.benn.2012.3956">Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012;<span class="ref-vol">97</span>:3956–64.</span> [<a href="/pubmed/22893714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22893714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.bertolini.2013.342">Bertolini S, Pisciotta L, Rabacchi C, Cefal&#x000f9; AB, Noto D, Fasano T, Signori A, Fresa R, Averna M, Calandra S. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. <span><span class="ref-journal">Atherosclerosis. </span>2013;<span class="ref-vol">227</span>:342–8.</span> [<a href="/pubmed/23375686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23375686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.brahm.2016.131">Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. <span><span class="ref-journal">Curr Opin Lipidol. </span>2016;<span class="ref-vol">27</span>:131–40.</span> [<a href="/pubmed/26709473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26709473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.burnett.2012.20">Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: familial hypobetalipoproteinaemia (APOB). <span><span class="ref-journal">Eur J Hum Genet. </span>2012:20.</span> [<a href="/pmc/articles/PMC3400740/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3400740</span></a>] [<a href="/pubmed/22588666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22588666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.calandra.2011.1885">Calandra S, Tarugi P, Speedy HE, Dean AF, Bertolini S, Shoulders CC. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. <span><span class="ref-journal">J Lipid Res. </span>2011;<span class="ref-vol">52</span>:1885–926.</span> [<a href="/pmc/articles/PMC3284125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3284125</span></a>] [<a href="/pubmed/21862702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21862702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.cariou.2011.258">Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. <span><span class="ref-journal">Atherosclerosis. </span>2011;<span class="ref-vol">216</span>:258–65.</span> [<a href="/pubmed/21596380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21596380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.civeira.2004.55">Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. <span><span class="ref-journal">Atherosclerosis. </span>2004;<span class="ref-vol">173</span>:55–68.</span> [<a href="/pubmed/15177124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15177124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.cohen.2006.1264">Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>:1264–72.</span> [<a href="/pubmed/16554528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16554528</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.cuchel.2014.2146">Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybj&#x000e6;rg-Hansen A, Watts GF, Averna M, Boileau C, Bor&#x000e9;n J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ, et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <span><span class="ref-journal">Eur Heart J. </span>2014;<span class="ref-vol">35</span>:2146–57.</span> [<a href="/pmc/articles/PMC4139706/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4139706</span></a>] [<a href="/pubmed/25053660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25053660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.de_castroor_s.2010.53">De Castro-Or&#x000f3;s I, Pocov&#x000ed; M, Civeira F. The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. <span><span class="ref-journal">Appl Clin Genet. </span>2010;<span class="ref-vol">3</span>:53–64.</span> [<a href="/pmc/articles/PMC3681164/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3681164</span></a>] [<a href="/pubmed/23776352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23776352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.dedoussis.2004.443">Dedoussis GV, Schmidt H, Genschel J. LDL-receptor mutations in Europe. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">24</span>:443–59.</span> [<a href="/pubmed/15523646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15523646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.degoma.2016.240">deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2016;<span class="ref-vol">9</span>:240–9.</span> [<a href="/pmc/articles/PMC5315030/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5315030</span></a>] [<a href="/pubmed/27013694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27013694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.dey.2013.932863">Dey A, Aggarwal R, Dwivedi S. Cardiovascular profile of xanthelasma palpebrarum. <span><span class="ref-journal">Biomed Res Int. </span>2013;<span class="ref-vol">2013</span>:932863.</span> [<a href="/pmc/articles/PMC3705817/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3705817</span></a>] [<a href="/pubmed/23865074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23865074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.elis.2011.223">Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. <span><span class="ref-journal">Am J Cardiol. </span>2011;<span class="ref-vol">108</span>:223–6.</span> [<a href="/pubmed/21545982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21545982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.fahed.2011.23">Fahed AC, Nemer GM. Familial hypercholesterolemia: the lipids or the genes? <span><span class="ref-journal">Nutr Metab (Lond). </span>2011;<span class="ref-vol">8</span>:23.</span> [<a href="/pmc/articles/PMC3104361/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3104361</span></a>] [<a href="/pubmed/21513517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21513517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF28">FDA. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. Available <a href="https://www.federalregister.gov/documents/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the-coadministration-with-statins" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2016. Accessed 10-21-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.fung.2011.2011">Fung M, Hill J, Cook D, Frohlich J. Case series of type III hyperlipoproteinemia in children. <span><span class="ref-journal">BMJ Case Rep. </span>2011 Jun 9;:2011.</span> [<a href="/pmc/articles/PMC3116222/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3116222</span></a>] [<a href="/pubmed/22691586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22691586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.gidding.2015.2167">Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS, et al.  The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. <span><span class="ref-journal">Circulation. </span>2015;<span class="ref-vol">132</span>:2167–92.</span> [<a href="/pubmed/26510694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26510694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.guyton.2013.1580">Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). <span><span class="ref-journal">J Am Coll Cardiol. </span>2013;<span class="ref-vol">62</span>:1580–4.</span> [<a href="/pmc/articles/PMC3862446/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3862446</span></a>] [<a href="/pubmed/23916935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23916935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.haradashiba.2012.1043">Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S. Guidelines for the management of familial hypercholesterolemia. <span><span class="ref-journal">J Atheroscler Thromb. </span>2012;<span class="ref-vol">19</span>:1043–60.</span> [<a href="/pubmed/23095242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23095242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.hegele.2009.4189">Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY, Anand S, Yusuf S, Huff MW, Wang J. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:4189–94.</span> [<a href="/pmc/articles/PMC2758142/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2758142</span></a>] [<a href="/pubmed/19656773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19656773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.hopkins.2011.s9">Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, et al.  Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <span><span class="ref-journal">J Clin Lipidol. </span>2011;<span class="ref-vol">5</span>:S9–17.</span> [<a href="/pubmed/21600530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21600530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.horsthemke.1987.144">Horsthemke B, Dunning A, Humphries S. Identification of deletions in the human low density lipoprotein receptor gene. <span><span class="ref-journal">J Med Genet. </span>1987;<span class="ref-vol">24</span>:144–7.</span> [<a href="/pmc/articles/PMC1049946/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1049946</span></a>] [<a href="/pubmed/3572996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3572996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.huang.1989.11394">Huang LS, Ripps ME, Korman SH, Deckelbaum RJ, Breslow JL. Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination. <span><span class="ref-journal">J Biol Chem. </span>1989;<span class="ref-vol">264</span>:11394–400.</span> [<a href="/pubmed/2567736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2567736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.huijgen.2012.354">Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJ. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2012;<span class="ref-vol">5</span>:354–9.</span> [<a href="/pubmed/22553281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22553281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.huxley.2003.22">Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HA, et al.  Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. <span><span class="ref-journal">Stroke. </span>2003;<span class="ref-vol">34</span>:22–5.</span> [<a href="/pubmed/12511745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12511745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.innerarity.1990.1337">Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. <span><span class="ref-journal">J Lipid Res. </span>1990;<span class="ref-vol">31</span>:1337–49.</span> [<a href="/pubmed/2280177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2280177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.kastelein.2008.1431">Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:1431–43.</span> [<a href="/pubmed/18376000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18376000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.khera.2016.2578">Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. <span><span class="ref-journal">J Am Coll Cardiol. </span>2016;<span class="ref-vol">67</span>:2578–89.</span> [<a href="/pmc/articles/PMC5405769/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5405769</span></a>] [<a href="/pubmed/27050191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27050191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.langsted.2016.577">Langsted A, Kamstrup PR, Benn M, Tybj&#x000e6;rg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. <span><span class="ref-journal">Lancet Diabetes Endocrinol. </span>2016;<span class="ref-vol">4</span>:577–87.</span> [<a href="/pubmed/27185354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27185354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.leigh.2008.485">Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. <span><span class="ref-journal">Ann Hum Genet. </span>2008;<span class="ref-vol">72</span>:485–98.</span> [<a href="/pubmed/18325082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18325082</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.martinez.2016.504">Martinez M, Brodlie S, Griesemer A, Kato T, Harren P, Gordon B, Parker T, Levine D, Tyberg T, Starc T, Cho I, Min J, Elmore K, Lobritto S, Hudgins LC. Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia. <span><span class="ref-journal">Am J Cardiol. </span>2016;<span class="ref-vol">118</span>:504–10.</span> [<a href="/pubmed/27365335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27365335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.motazacker.2012.1360">Motazacker MM, Pirruccello J, Huijgen R, Do R, Gabriel S, Peter J, Kuivenhoven JA, Defesche JC, Kastelein JJ, Hovingh GK, Zelcer N, Kathiresan S, Fouchier SW. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. <span><span class="ref-journal">Eur Heart J. </span>2012;<span class="ref-vol">33</span>:1360–6.</span> [<a href="/pubmed/22408029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22408029</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.naoumova.2005.2654">Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C, Soutar AK. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>2005;<span class="ref-vol">25</span>:2654–60.</span> [<a href="/pubmed/16224054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16224054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.naukkarinen.2006.285">Naukkarinen J, Ehnholm C, Peltonen L. Genetics of familial combined hyperlipidemia. <span><span class="ref-journal">Curr Opin Lipidol. </span>2006;<span class="ref-vol">17</span>:285–90.</span> [<a href="/pubmed/16680034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16680034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.ned.2011.rrn1238">Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). <span><span class="ref-journal">PLoS Curr. </span>2011;<span class="ref-vol">3</span>:RRN1238.</span> [<a href="/pmc/articles/PMC3102597/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3102597</span></a>] [<a href="/pubmed/21633520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21633520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Bor&#x000e9;n J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybj&#x000e6;rg-Hansen A, et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <span><span class="ref-journal">Eur Heart J. </span>2013;<span class="ref-vol">34</span>:3478–90a.</span> [<a href="/pmc/articles/PMC3844152/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3844152</span></a>] [<a href="/pubmed/23956253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23956253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.pandit.2008.1333">Pandit S, Wisniewski D, Santoro JC, Ha S, Ramakrishnan V, Cubbon RM, Cummings RT, Wright SD, Sparrow CP, Sitlani A, Fisher TS. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. <span><span class="ref-journal">J Lipid Res. </span>2008;<span class="ref-vol">49</span>:1333–43.</span> [<a href="/pubmed/18354137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18354137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.perez_de_isla.2016.1278">Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Mu&#x000f1;iz O, Fuentes F, Diaz-Diaz JL, de Andr&#x000e9;s R, Zamb&#x000f3;n D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Mu&#x000f1;oz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badim&#x000f3;n L, Mata P, et al.  Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up. <span><span class="ref-journal">J Am Coll Cardiol. </span>2016;<span class="ref-vol">67</span>:1278–85.</span> [<a href="/pubmed/26988947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26988947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2013.7">Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>:7–8.</span> [<a href="/pubmed/23122767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23122767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2015.341">Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2015;<span class="ref-vol">385</span>:341–50.</span> [<a href="/pubmed/25282520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25282520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2012.262">Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. <span><span class="ref-journal">Atherosclerosis. </span>2012;<span class="ref-vol">223</span>:262–8.</span> [<a href="/pubmed/22398274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22398274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2010.998">Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">375</span>:998–1006.</span> [<a href="/pubmed/20227758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20227758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2016a.238">Raal FJ, Sjouke B, Hovingh GK, Isaac BF. Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study. <span><span class="ref-journal">Atherosclerosis. </span>2016a;<span class="ref-vol">248</span>:238–44.</span> [<a href="/pubmed/27017151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27017151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.raal.2016b.1458">Raal FJ, Sjouke B, Hovingh GK, Isaac BF. Retrospective analysis of cohort database: phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. <span><span class="ref-journal">Data Brief. </span>2016b;<span class="ref-vol">7</span>:1458–62.</span> [<a href="/pmc/articles/PMC4857223/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4857223</span></a>] [<a href="/pubmed/27182539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27182539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.rader.2003.1795">Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">111</span>:1795–803.</span> [<a href="/pmc/articles/PMC161432/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC161432</span></a>] [<a href="/pubmed/12813012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12813012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.reiner.2011.1769">Reiner &#x0017d;, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, et al.  ESC/EAS Guidelines for the management of dyslipidaemias. <span><span class="ref-journal">Eur Heart J. </span>2011;<span class="ref-vol">32</span>:1769–818.</span> [<a href="/pubmed/21712404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21712404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.scientific_steering_committee.1991.893">Scientific Steering Committee.  Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. <span><span class="ref-journal">BMJ. </span>1991;<span class="ref-vol">303</span>:893–6.</span> [<a href="/pmc/articles/PMC1671226/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1671226</span></a>] [<a href="/pubmed/1933004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1933004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.simard.2004.202">Simard LR, Viel J, Lambert M, Paradis G, Levy E, Delvin EE, Mitchell GA. The Delta&#x0003e;15 Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">65</span>:202–8.</span> [<a href="/pubmed/14756670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14756670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.slack.1969.1380">Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. <span><span class="ref-journal">Lancet. </span>1969;<span class="ref-vol">2</span>:1380–2.</span> [<a href="/pubmed/4188273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4188273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.starr.2008.791">Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, Neil HA, Humphries SE. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. <span><span class="ref-journal">Clin Chem Lab Med. </span>2008;<span class="ref-vol">46</span>:791–803.</span> [<a href="/pubmed/18601600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18601600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.stone.1974.476">Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. <span><span class="ref-journal">Circulation. </span>1974;<span class="ref-vol">49</span>:476–88.</span> [<a href="/pubmed/4813182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4813182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.stone.2014.2889">Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <span><span class="ref-journal">J Am Coll Cardiol. </span>2014;<span class="ref-vol">63</span>:2889–934.</span> [<a href="/pubmed/24239923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24239923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.talmud.2013.1293">Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>:1293–301.</span> [<a href="/pubmed/23433573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23433573</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.tsouli.2005.236">Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. <span><span class="ref-journal">Eur J Clin Invest. </span>2005;<span class="ref-vol">35</span>:236–44.</span> [<a href="/pubmed/15816992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15816992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.usifo.2012.387">Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, Orengo CA, Martin AC, Celli J, Humphries SE. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. <span><span class="ref-journal">Ann Hum Genet. </span>2012;<span class="ref-vol">76</span>:387–401.</span> [<a href="/pubmed/22881376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22881376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.versmissen.2008.a2423">Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. <span><span class="ref-journal">BMJ. </span>2008;<span class="ref-vol">337</span>:a2423.</span> [<a href="/pmc/articles/PMC2583391/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2583391</span></a>] [<a href="/pubmed/19001495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19001495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.vuorio.2013.315">Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? <span><span class="ref-journal">Atherosclerosis. </span>2013;<span class="ref-vol">226</span>:315–20.</span> [<a href="/pubmed/23141908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23141908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.wald.2016.1628">Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-parent familial hypercholesterolemia screening in primary care. <span><span class="ref-journal">N Engl J Med. </span>2016;<span class="ref-vol">375</span>:1628–37.</span> [<a href="/pubmed/27783906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27783906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.whitfield.2004.1725">Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. <span><span class="ref-journal">Clin Chem. </span>2004;<span class="ref-vol">50</span>:1725–32.</span> [<a href="/pubmed/15308601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15308601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.wierzbicki.2008.a1095">Wierzbicki AS, Humphries SE, Minhas R, et al.  Familial hypercholesterolaemia: summary of NICE guidance. <span><span class="ref-journal">BMJ. </span>2008;<span class="ref-vol">337</span>:a1095.</span> [<a href="/pubmed/18753174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18753174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hyperchol.REF.williams.1993.319s">Williams RR, Hunt SC, Hopkins PN, Wu LL, Hasstedt SJ, Berry TD, Barlow GK, Stults BM, Schumacher MC, Ludwig EH, Elbein SC, Wilson DE, Lifton RP, Lalouel JM. Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. <span><span class="ref-journal">Am J Hypertens. </span>1993;<span class="ref-vol">6</span>:319S–327S.</span> [<a href="/pubmed/8297539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8297539</span></a>]</div></li></ul></div></div><div id="hyperchol.Chapter_Notes"><h2 id="_hyperchol_Chapter_Notes_">Chapter Notes</h2><div id="hyperchol.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 December 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 January 2014 (me) Review posted live</div></li><li class="half_rhythm"><div>5 August 2013 (jl) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK174884</span><span class="label">PMID: <a href="/pubmed/24404629" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">24404629</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/fhm/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hi/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK174884&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK174884/?report=reader">PubReader</a></li><li><a href="/books/NBK174884/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK174884" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK174884" style="display:none" title="Cite this Page"><div class="bk_tt">Youngblom E, Pariani M, Knowles JW. Familial Hypercholesterolemia. 2014 Jan 2 [Updated 2016 Dec 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK174884/pdf/Bookshelf_NBK174884.pdf">PDF version of this page</a> (708K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hyperchol.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hyperchol.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#hyperchol.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hyperchol.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hyperchol.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hyperchol.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hyperchol.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hyperchol.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hyperchol.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hyperchol.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hyperchol.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hyperchol.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10842[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PPP1R17</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2053[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">EPHX2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=338[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">APOB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3949[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LDLR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2690[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GHR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=255738[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PCSK9</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=336[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">APOA2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3066746" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3066746" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3066746" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3066746" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23074505" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Low-density lipoprotein apheresis: an evidence-based analysis.</a><span class="source">[Ont Health Technol Assess Ser....]</span><div class="brieflinkpop offscreen_noflow">Low-density lipoprotein apheresis: an evidence-based analysis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Medical Advisory Secretariat.. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ont Health Technol Assess Ser. 2007; 7(5):1-101. Epub 2006 Nov 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27559556" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force</a><span class="source">[ 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">2016 Aug</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23461430" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</a><span class="source">[J Manag Care Pharm. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Robinson JG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Manag Care Pharm. 2013 Mar; 19(2):139-49. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27967828" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Homozygous familial hypercholesterolaemia: update on management.</a><span class="source">[Paediatr Int Child Health. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Homozygous familial hypercholesterolaemia: update on management.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">France M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Paediatr Int Child Health. 2016 Nov; 36(4):243-247. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12553167" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.</a><span class="source">[Dan Med Bull. 2002]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jensen HK. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dan Med Bull. 2002 Nov; 49(4):318-45. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=24404629" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=24404629" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419cb75f66d18aaa23d4d">Familial Hypercholesterolemia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Familial Hypercholesterolemia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A37F7E04089E100000000076902A6&amp;ncbi_session=CE8A37F7E0419CA1_1897SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK174884%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK174884&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK174884/&amp;ncbi_pagename=Familial Hypercholesterolemia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A37F7E0419CA1_1897SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>